Related Experiment Video
Updated: Apr 15, 2026

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
Copper Dyshomeostasis Affects α-Synuclein Clearance Mechanisms in Parkinson's Disease: Insights from In Vitro Models
Debora Musarò1, Marco Greco1, Martina Lanza1
1Department of Experimental Medicine, University of Salento, Via Lecce-Monteroni, 73100 Lecce, Italy.
Abstract:
Parkinson's disease (PD) is characterized by the progressive degeneration of dopaminergic neurons and the accumulation of α-synuclein-rich inclusions, largely resulting from impaired protein clearance mechanisms. Copper is an essential redox-active metal in the central nervous system (CNS), but alterations in its homeostasis can promote oxidative stress, mitochondrial dysfunction, and proteostatic failure. In vitro studies indicate that copper can promote α-synuclein misfolding, enhance oxidative stress, and interfere with both the ubiquitin-proteasome system (UPS) and the autophagy-lysosome pathway (ALP). In this review, we critically evaluate mechanistic evidence from cellular models, integrating available animal and clinical data to assess the biological significance of copper-mediated impairment of α-synuclein clearance. We highlight the current research, identify methodological limitations, and discuss whether copper imbalance acts as a primary pathogenic trigger or as a disease-modifying amplifier of proteostatic failure. Furthermore, we consider the translational implications of selectively modulating intracellular copper pools as a therapeutic strategy in PD. Finally, we will highlight unresolved issues, methodological limitations, and emerging targeted therapeutic prospects.
Related Concept Videos
Neural Regulation
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Lysosomal Hydrolases
Drugs Affecting Neurotransmitter Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

